FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793689286> ?p ?o ?g. }

• W2793689286 endingPage "772" @default.
• W2793689286 startingPage "764" @default.
• W2793689286 abstract "Objectives A global unmet medical need exists for effective treatments for persistent, recurrent, or metastatic cervical cancer, as patients have a short life expectancy. Recently, immunotherapies have shown promising survival benefits for patients with advanced forms of cancer. Axalimogene filolisbac (ADXS11-001), a Listeria monocytogenes immunotherapy with a broad effect on the immune system, is under investigation for treatment of human papillomavirus–associated cancers including cervical cancer. Methods This phase 2 study evaluated the safety and efficacy of ADXS11-001, administered with or without cisplatin, in patients with recurrent/refractory cervical cancer following prior chemotherapy and/or radiotherapy. A total of 109 patients were treated, and 69 were evaluable for tumor response at equal to or more than 3 months postbaseline. Results Median overall survival (OS) was comparable between treatment groups (ADXS11-001: 8.28 months; 95% confidence interval [CI], 5.85–10.5 months; ADXS11-001 + cisplatin: 8.78 months; 95% CI, 7.4–13.3 months). The 12- and 18-month milestone OS rates were 30.9% versus 38.9%, and 23.6% versus 25.9% for each group, respectively (34.9% and 24.8% combined). Median progression-free survival (6.10 vs 6.08 months) and the overall response rate (17.1% vs 14.7%) were similar for both groups. ADXS11-001 was generally well tolerated; adverse events were predominantly mild to moderate in severity and not related to treatment. More adverse events were reported in the combination group (429 vs 275). Conclusions These promising safety and efficacy results, including the encouraging 12-month 34.9% combined OS rate, warrant further investigation of ADXS11-001 for treatment of recurrent/refractory cervical cancer." @default.
• W2793689286 created "2018-03-29" @default.
• W2793689286 creator A5002075684 @default.
• W2793689286 creator A5004920779 @default.
• W2793689286 creator A5017657024 @default.
• W2793689286 creator A5021079901 @default.
• W2793689286 creator A5029096381 @default.
• W2793689286 creator A5058903725 @default.
• W2793689286 creator A5061250035 @default.
• W2793689286 date "2018-05-01" @default.
• W2793689286 modified "2023-10-15" @default.
• W2793689286 title "A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes–Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer" @default.
• W2793689286 cites W1926137745 @default.
• W2793689286 cites W1932754573 @default.
• W2793689286 cites W1986406829 @default.
• W2793689286 cites W1986584852 @default.
• W2793689286 cites W1992512667 @default.
• W2793689286 cites W2006287686 @default.
• W2793689286 cites W2018839954 @default.
• W2793689286 cites W2023905742 @default.
• W2793689286 cites W2061566045 @default.
• W2793689286 cites W2079730922 @default.
• W2793689286 cites W2100756525 @default.
• W2793689286 cites W2118508302 @default.
• W2793689286 cites W2126768246 @default.
• W2793689286 cites W2126834211 @default.
• W2793689286 cites W2133075384 @default.
• W2793689286 cites W2138983746 @default.
• W2793689286 cites W2171725862 @default.
• W2793689286 cites W2202895600 @default.
• W2793689286 cites W2470768421 @default.
• W2793689286 cites W2626995743 @default.
• W2793689286 doi "https://doi.org/10.1097/igc.0000000000001235" @default.
• W2793689286 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5929492" @default.
• W2793689286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29538258" @default.
• W2793689286 hasPublicationYear "2018" @default.
• W2793689286 type Work @default.
• W2793689286 sameAs 2793689286 @default.
• W2793689286 citedByCount "109" @default.
• W2793689286 countsByYear W27936892862018 @default.
• W2793689286 countsByYear W27936892862019 @default.
• W2793689286 countsByYear W27936892862020 @default.
• W2793689286 countsByYear W27936892862021 @default.
• W2793689286 countsByYear W27936892862022 @default.
• W2793689286 countsByYear W27936892862023 @default.
• W2793689286 crossrefType "journal-article" @default.
• W2793689286 hasAuthorship W2793689286A5002075684 @default.
• W2793689286 hasAuthorship W2793689286A5004920779 @default.
• W2793689286 hasAuthorship W2793689286A5017657024 @default.
• W2793689286 hasAuthorship W2793689286A5021079901 @default.
• W2793689286 hasAuthorship W2793689286A5029096381 @default.
• W2793689286 hasAuthorship W2793689286A5058903725 @default.
• W2793689286 hasAuthorship W2793689286A5061250035 @default.
• W2793689286 hasBestOaLocation W27936892862 @default.
• W2793689286 hasConcept C121332964 @default.
• W2793689286 hasConcept C121608353 @default.
• W2793689286 hasConcept C126322002 @default.
• W2793689286 hasConcept C141071460 @default.
• W2793689286 hasConcept C142424586 @default.
• W2793689286 hasConcept C143998085 @default.
• W2793689286 hasConcept C197934379 @default.
• W2793689286 hasConcept C2776694085 @default.
• W2793689286 hasConcept C2777701055 @default.
• W2793689286 hasConcept C2778220009 @default.
• W2793689286 hasConcept C2778239845 @default.
• W2793689286 hasConcept C44249647 @default.
• W2793689286 hasConcept C509974204 @default.
• W2793689286 hasConcept C71924100 @default.
• W2793689286 hasConcept C87355193 @default.
• W2793689286 hasConcept C90924648 @default.
• W2793689286 hasConceptScore W2793689286C121332964 @default.
• W2793689286 hasConceptScore W2793689286C121608353 @default.
• W2793689286 hasConceptScore W2793689286C126322002 @default.
• W2793689286 hasConceptScore W2793689286C141071460 @default.
• W2793689286 hasConceptScore W2793689286C142424586 @default.
• W2793689286 hasConceptScore W2793689286C143998085 @default.
• W2793689286 hasConceptScore W2793689286C197934379 @default.
• W2793689286 hasConceptScore W2793689286C2776694085 @default.
• W2793689286 hasConceptScore W2793689286C2777701055 @default.
• W2793689286 hasConceptScore W2793689286C2778220009 @default.
• W2793689286 hasConceptScore W2793689286C2778239845 @default.
• W2793689286 hasConceptScore W2793689286C44249647 @default.
• W2793689286 hasConceptScore W2793689286C509974204 @default.
• W2793689286 hasConceptScore W2793689286C71924100 @default.
• W2793689286 hasConceptScore W2793689286C87355193 @default.
• W2793689286 hasConceptScore W2793689286C90924648 @default.
• W2793689286 hasIssue "4" @default.
• W2793689286 hasLocation W27936892861 @default.
• W2793689286 hasLocation W27936892862 @default.
• W2793689286 hasLocation W27936892863 @default.
• W2793689286 hasLocation W27936892864 @default.
• W2793689286 hasOpenAccess W2793689286 @default.
• W2793689286 hasPrimaryLocation W27936892861 @default.
• W2793689286 hasRelatedWork W1971929983 @default.
• W2793689286 hasRelatedWork W2021865845 @default.
• W2793689286 hasRelatedWork W2066496973 @default.
• W2793689286 hasRelatedWork W2091461259 @default.
• W2793689286 hasRelatedWork W2100875939 @default.

• next